News
MRNA
24.16
-5.24%
-1.34
Alnylam drops Covid vaccine patent case against Pfizer, BioNTech for now
Reuters · 2h ago
Bernstein Sticks to Their Hold Rating for Moderna (MRNA)
TipRanks · 10h ago
Moderna Faces Revenue Challenges Amid Disappointing RSV Vaccine Launch and Limited Near-Term Growth Prospects
TipRanks · 12h ago
S&P 500 turns positive for 2025; here are its best and worst YTD performers
Seeking Alpha · 23h ago
MRNA Quantitative Stock Analysis - Benjamin Graham
NASDAQ · 23h ago
Most shorted S&P500 stocks in April
Seeking Alpha · 1d ago
VOO ETF News, 5/13/2025
TipRanks · 1d ago
Notable Monday Option Activity: WERN, WWD, MRNA
NASDAQ · 2d ago
'Trump To Sign Order To Cut Some U.S. Drug Prices To Match Those Abroad' - CNBC
Benzinga · 2d ago
Eli Lilly Strikes $1B Biotech Deal with Creyon Bio to Accelerate AI-Powered RNA Drug Discovery
TipRanks · 2d ago
Why Moderna Merged Its Tech and HR Departments
The Wall Street Journal · 2d ago
RPT-BUZZ-US stocks weekly: Trade down 
Reuters · 2d ago
Weekly Report: what happened at MRNA last week (0505-0509)?
Weekly Report · 2d ago
Notable healthcare headlines for the week: Viatris, Novavax and UnitedHealth in focus
Seeking Alpha · 3d ago
Invesco Equally-Weighted S&P 500 Fund Q1 2025 Commentary
Seeking Alpha · 3d ago
Moderna’s Stock Tumbles Amid Revenue Drop and Delays
TipRanks · 4d ago
What Moved Markets This Week
Seeking Alpha · 4d ago
BUZZ-US stocks weekly: Trade down 
Reuters · 4d ago
VOO ETF News, 5/9/2025
TipRanks · 5d ago
FDA to speed up AI rollout to accelerate drug reviews
Seeking Alpha · 6d ago
More
Webull provides a variety of real-time MRNA stock news. You can receive the latest news about Moderna through multiple platforms. This information may help you make smarter investment decisions.
About MRNA
More
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).